Phexxi®
Contraception
ApprovedCommercial growth and geographic expansion
Key Facts
About Organon
Organon is a publicly traded, diversified healthcare company that emerged as a spin-off from Merck & Co. (known as MSD outside the U.S. and Canada) in June 2021. The company's portfolio is built around three core pillars: a leading women's health franchise, a growing portfolio of biosimilars, and a stable of established brands across various therapeutic areas. With a global commercial footprint and a commitment to addressing unmet needs, particularly in women's health, Organon aims to drive sustainable growth through its existing portfolio, pipeline development, and strategic business development.
View full company profileOther Contraception Drugs
| Drug | Company | Phase |
|---|---|---|
| Elyea™ (etonogestrel/ethinyl estradiol vaginal system) | Organon | Approved |
| APR-TD (Annual Performer Ring) | Organon | Development |